Clinical Trial Update: A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders [Phase 1]

View source ↗

Summary

Phase I/II trial update of Recombinant-Methionyl Human Stem Cell Factor (SCF) in adults with sickling disorders; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobin Sc Disease
• Sickle Cell Disease

Drugs mentioned

• Recombinant-Methionyl Human Stem Cell Factor (SCF) (recombinant-methionyl human stem cell factor)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Hemoglobin SC Disease, Sickle Cell Anemia | Phase 1 | Status: COMPLETED